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ABSTRACT: The functionality of a newly developed silicone oil-free (SOF) syringe system, of which the plunger stopper is coated by a
novel coating technology (i-coatingTM), was assessed. By scanning electron microscopy observations and other analysis, it was confirmed
that the plunger stopper surface was uniformly covered with the designed chemical composition. A microflow imaging analysis showed
that the SOF system drastically reduced both silicone oil (SO) doplets and oil-induced aggregations in a model protein formulation, whereas
a large number of subvisible particles and protein aggregations were formed when a SO system was used. Satisfactory container closure
integrity (CCI) was confirmed by means of dye and microorganism penetration studies. Furthermore, no significant difference between the
break loose and gliding forces was observed in the former, and stability studies revealed that the SOF system could perfectly show the
aging independence in break loose force observed in the SO system. The results suggest that the introduced novel SOF system has a great
potential and represents an alternative that can achieve very low subvisible particles, secure CCI, and the absence of a break loose force.
In particular, no risk of SO-induced aggregation can bring additional value in the highly sensitive biotech drug market. C© 2014 Wiley
Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:1520–1528, 2014
Keywords: protein aggregation; surface chemistry; particle size; stability; imaging analysis; prefilled syringe; physical stability; silicone
oil; gliding force; container closure integrity
INTRODUCTION
The recently increased interest in prefilled syringes (PFS) is
largely driven by many advantages against traditional am-
poules and vials, such as allowing quick and accurate dosing,
minimizing dosing errors, reducing the risk of biological con-
tamination, enhanced convenience and ease of use, preventing
of overfill, and so on. On increasing number of available bio-
logical drugs, the demand for the use of PFS has considerably
increased in recent years.
Silicone oil (SO) is widely used as a lubricant in syringes
to ensure a smooth gliding behavior of the plunger inside
the barrel. Furthermore, siliconization effectively prevents the
plunger stoppers from sticking together during the material
shipping and manufacturing process. It is also important to
minimize the mechanical force when the plunger stoppers are
inserted into a barrel using a mechanical stoppering machine.
Siliconization is therefore essential to the process capability
of the SO-lubricated syringe. However, it is known that the
use of SO-coated syringes leads to difficulties in case of some
silicone-sensitive drugs, such as protein-based drugs. For ex-
ample, several reports in the 1980s implicated that the ingress
of SO from disposable syringes caused aggregation of human
insulin.1–5 Researchers continue to seek how SO can accelerate
the intermolecular interactions of proteins, and stability stud-
ies revealed that the oil could negatively affect the chemical
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and physical stability of the protein formulation, thereby caus-
ing a loss of soluble proteins.6,7 Additional works have been
performed to assess the effects of ionic strength and the type
of surfactants that can be used to minimize the risk of a SO-
induced aggregation.8–10
Silicone oil-induced aggregation has now become one of the
most frequently discussed subjects in the field of PFS, particu-
larly for developers of highly sensitive biotech drugs.6,11,12 Once
SO detaches from the inner wall of the barrel, oil droplets are
formed that contribute to the population of subvisible particles.
The levels of visible and subvisible particles have become criti-
cal also to the quality of drug products in PFS.13–15 To mitigate
the risk, the reduction of the SO quantity may be one of the
options to be considered, but this may not be adequate because
siliconization is essential to ensure the functionality of the sy-
ringe over the shelf life of the product, and even if the quantity
of SO is reduced, the risk of SO-induced aggregation cannot be
eliminated completely.
Under such circumstances described above, the demand for
the SO-free (SOF) system has been rising, and various tech-
nologies have been proposed so far.16 Most of them are coating
technologies in which the surface of the barrel and/or plunger
stopper is coated with a lubricious, compatible, and physic-
ochemically inert material. In response to this unmet need,
Terumo created an innovative coating technology, which re-
sulted in the successful introduction of an SOF system for
polymer-based PFS in 2005 within the Japanese market that
is still supplied in the market today.
Through continued research and development, Terumo has
introduced the next generation of SOF coating technology
called i-coatingTM for use on plunger stoppers. By using this
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technology, novel SOF system for prefillable syringes can be
accomplished.
The purpose of the present study is to characterize the func-
tionality of this novel SOF system by comparing it with current
SO system. In this paper, the coated surface was character-
ized by means of scanning electron microscopic (SEM) obser-
vations, FTIR analysis, and X-ray photoelectron spectroscopy
(XPS), and the influences on the generation of subvisible parti-
cles, container closure integrity (CCI), and break loose gliding
forces as important attributes of PFS were assessed.
MATERIALS AND METHODS
Materials
PLAJEXTM syringe [Polymer based prefillable syringe, 1 mL
long staked needle (27G)] (SOF syringe system) was provided
by Terumo Corporation (Tokyo, Japan), which is a newly devel-
oped prefillable syringe with a polymer barrel made of cyclic
olefin polymer and a butyl rubber plunger stopper coated by
use of the i-coatingTM technology (a proprietary coating). The
corresponding PLAJEXTM syringe lubricated by SO with an
uncoated plunger stopper (SO system for comparison) was also
provided by Terumo Corporation. A butyl rubber sheet of 1 mm
in thickness was obtained from Asahi Rubber Inc. (Saitama,
Japan). Using the i-coatingTM technology, the coated butyl rub-
ber sheet was provided by Terumo Corporation. As a reference
sample, SO-coated butyl rubber sheet was also provided by
Terumo Corporation. L-Asparaginase (Asp) was purchased from
Prospec-Tany TechnoGene Ltd. (Rehovot, Israel); human IgG
was purchased from Equitech-Bio Inc. (Kerrville, Texas, USA);
albumin from bovine serum (BSA) and lysozyme from chicken
egg white (Lyso) were purchased from Sigma–Aldrich Company
LLC., (St. Louis, MO, USA), respectively. Triptic soy agar and
triptic soy broth (TSB) were purchased from Becton, Dickin-
son and Company (Franklin lakes, NJ, USA). Isotonic sodium
chloride solution and commercially available saline solution
of Japanese Pharmacopoeia grade (JP grade) were obtained
from Terumo Corporation. Water for injection (20 mL) was
JP grade and purchased from Otsuka Pharmaceutical Com-
pany Ltd., (Tokyo, Japan). Crystal violet and all buffer salts
(sodium phosphate monobasic, sodium phosphate dibasic, and
sodium chloride) were purchased from Kanto Chemical Corpo-
ration (Tokyo, Japan). All other chemicals and reagents were
of analytical grade.
Scanning Electron Microscopy
Scanning electron microscopic observations were performed us-
ing a microscope model KEYENCE VE8800 (Tokyo, Japan) to
assess the integrity of the coating layer of the plunger stopper.
The surface and the cross-section of the coated and uncoated
plunger stoppers were observed with magnifications of ×300 or
×1000. To produce a cross-section, a sample was cut vertically
by a razor. After platinum was sputtered, the top surfaces and
cross-sections of the samples were observed at an acceleration
voltage of 1.7 kV.
Fourier Transform-Infrared Spectroscopy
The top surface of the uncoated and coated plunger stop-
per was analyzed using an FTIR spectrometer (Spectrum100;
PerkinElmer, Wellesley, Massachusetts) equipped with a uni-
versal attenuated total reflectance (ATR) sampling accessory.
ATR–FTIR spectra were recorded at a resolution of 4 cm−1 and
16 scans per specimen were averaged in a wavenumber range
from 650 to 4000 cm−1.
X-Ray Photoelectron Spectroscopy
The top surface of the coated plunger stopper was analyzed
by means of XPS (Axis-NOVA, Kratos, Manchester, UK) using
monochromated Al-K" (1486.6 eV) X-ray radiation. The X-ray
tube was operated at 15 kV and 20 mA. The take-off angle
between the sample plane and the axis of the analyzer was
90◦. A pass energy of 80 eV was chosen for the acquisition of
a survey spectrum (0–1000 eV). The pressure was maintained
below 10−8 Pa during the measurements.
Protein Aggregation Study
Ten thousand units of Asp were dissolved in 2 mL of water for
injection (JP grade). After complete dissolution, the syringes
were filled with 1.0 mL of the Asp solution and stopped with
plunger stoppers leaving a predetermined headspace of 0.4 mL.
The syringes were also filled with 1.0 mL of pure water for in-
jection as reference for the protein aggregation study. After
filling, the syringes were shaken in a shaker (SR-I; TAITEC
Company Ltd., Saitama, Japan) for 30 min at 250 rpm at room
temperature. Immediately after shaking, aliquots of the sam-
ple solution were drawn out through a needle by actuation of
the plunger stopper and analyzed for particle concentration by
micro-flow imaging (MFI). DPA4200 (Brightwell Technologies
Inc., Ottawa, Canada) was used for the measurement of subvis-
ible particles. The number of subvisible particles whose equiva-
lent circular diameter is larger than 5 :m was analyzed in this
study. Moreover, to obtain information about particle shape,
an aspect ratio (AR) filter was employed to distinguish circu-
lar (AR ≥ 0.85) and noncircular particles (AR < 0.85). Here,
particles having AR ≥ 0.85 and AR < 0.85 are regarded as
SO droplets and SO-induced protein aggregates, respectively,
according to previous studies.17,18 In addition, IgG, BSA, and
Lyso were dissolved at 1 mg/mL in a buffer (10 mM Na2HPO4,
130 mM NaCl, pH 7.2) and used.6 Subvisible particles of these
protein solutions were also measured in the same manner as
described above.
Dye Penetration Study
To assess the CCI of the syringes, a dye penetration study was
conducted. One milliliter of water was filled into the syringes
and the headspace of the syringes was adjusted to predeter-
mined distances (0.5, 0.75, 1.0, and 1.35 mm) by pushing the
plunger stopper down. A small amount (0.15 mL) of 1.0% crys-
tal violet aqueous solution was then placed into the space be-
tween the plunger stopper and the flange. The sample syringes
were vertically placed in a decompressed chamber (adjusted
at −19.6 kPa with respect to normal atmospheric pressure).
After 2 h, the water in the syringes was carefully drawn out
through a needle and photometrically analyzed to determine
the dye concentration using a spectrophotometer SHIMADZU
UV-2450 (Kyoto, Japan).
Microorganism Penetration Study
The study was performed according to the method proposed
by the pharmaceutical inspection convention.19 In addition to
the intact PLAJEXTM syringe, a PLAJEXTM syringe with a pin-
hole (size of about 8 :m) on the pathway of the barrel was
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used as a positive control. All the syringe samples were steril-
ized in an autoclave. The TSB culture medium was filled into
the sterilized syringes by aseptic manipulation. All the sam-
ples were cultured at 31 ± 1◦C for 7 days. After confirmation
of sterility, they were immersed into a bacterial broth (106
cfu/mL) in a pressurized chamber (+0.02 MPa above normal
atmospheric pressure) for 30 min and, then, were taken and
the barrel surfaces were washed by water for injection and
70% ethanol. The pinhole of the positive control was closed by
glue. After that, the samples were incubated at 31 ± 1◦C for 14
days. The occurrence of microbial growth was judged by visual
observation.
Dynamic Friction Coefficient Study
The dynamic friction coefficient was analyzed using a
continuous-loading surface property tester (TRIBOGEAR;
Shinto Scientific Company Ltd., Tokyo, Japan). A steel ball
with 10 mm in diameter was put on the surface of the sam-
ple sheet (40 × 40 mm2 in size) and rolled on the surface along
a distance of 20 mm at a speed of 3.0 mm/s at room temperature
to measure the dynamic friction coefficient. In accordance with
previous studies, the amount of SO on the sheet was adjusted
such that it was equivalent to the amount that is realistically
present in a prefillable syringe (0.7 mg/syringe).16,20,21
Gliding Force Measurement
Gliding forces were measured using a universal testing ma-
chine (EZtest; SHIMADZU corporation, Kyoto, Japan). Each
syringe (the SO and the SOF system) was filled with 1.2 mL of
water for injection. Then, the distal end of the syringe and the
proximal end of the plunger were attached to the fixing portions
of the tester. The plunger was moved downward at room temper-
ature and the force required for gliding the plunger stopper and
plunger were recorded. The stroke distance and the crosshead
speed were set at 30 mm and 200 mm/min, respectively. The
maximum gliding force between 0 and 5 mm of stroke distance
was defined as “break loose force.”
For the stability studies, the water-filled syringes (the SO
and the SOF system) were stored at 4◦C, 25◦C, and 40◦C
for predetermined periods of time (0, 2, 4, 6, 8, 12, and 24




The plunger stoppers coated by i-coatingTM were observed by
SEM to verify the integrity of the coating. The surface and
cross-sectional images of uncoated plunger stoppers were rela-
tively rough (Figs. 1a and 1b), whereas a quite smooth surface
was observed in case of the coated plunger stopper (Fig. 1c).
In addition, as shown in Figure 1d, the coated layer was quite
uniform with a thickness of about 5–10 :m. By this SEM obser-
vation, it was confirmed that plunger stoppers provided with
the SOF system are uniformly coated without any defects by
means of i-coatingTM.
Figure 1. SEM micrographs of the surface and cross-section of the plunger stoppers coated by i-coatingTM. (a) Top surface of an uncoated
plunger stopper (×300), (b) cross-section of an uncoated plunger stopper (×1000), (c) top surface of a coated plunger stopper (×300), and (d)
cross-section of a coated plunger stopper (×1000).
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Figure 2. FTIR spectrum of (a) the surface of the coated plunger stopper, (b) reference spectrum of silicone, and (c) the surface of the uncoated
plunger stopper. The peaks between (a) and (b) at 2962 cm−1 (methyl CH), 1260 cm−1 (Si–CH3), 1089 cm−1 (Si–O–Si), 1013 cm−1 (Si–C), and
799 cm−1 [Si–(CH3)2] coincided well with those of the reference spectrum. (d) XPS survey spectrum, measured at the top surface of the coated
plunger stopper.
FTIR and XPS Analysis
Figure 2a shows a FTIR spectrum of the surface of a coated
plunger stopper. The peaks observed around 2962 cm−1 (methyl
CH), 1260 cm−1 (Si–CH3), 1089 cm−1 (Si–O–Si), 1013 cm−1 (Si–
C), and 799 cm−1 [Si–(CH3)2] well coincided with those of the
FTIR reference spectrum (Fig. 2b), clearly indicating that the
surface layer of the plunger stopper was formed by the silicone-
based resin, as intended. As a control, Figure 2c shows the
FTIR spectrum of the surface of an uncoated plunger stopper.
As seen in Figure 2c, butyl rubber-related peaks were observed
around 1472 cm−1 (CH2, CH3), 1390 cm−1 (tert-butyl CC), and
1366 cm−1 (tert-butyl CH). In contrast, these distinctive peaks
were not observed in Figure 2a. This FTIR spectra compari-
son also helped confirm that the plunger stoppers equipped in
the SOF system were uniformly coated by silicone-based resin
without exposure of the uncoated butyl rubber surface.
Figure 2d shows the XPS survey spectrum of the top
surface of the coated plunger stopper. As evident, signals
corresponding to O1s, C1s, Si2s, and Si2p were observed.
The quantitative ratio of these elements was found to be
C(1s):O(1s):Si(2p) = 1.00:0.44:0.46, quite close to the theoreti-
cal ratio (1.00:0.50:0.50) calculated from the composition of the
silicone-based resin of i-coatingTM. Thus, FTIR and XPS analy-
sis showed in mutual agreement that the surface of the coated
plunger stopper was certainly covered by silicone-based resin
employing the i-coatingTM technology.
Protein Aggregation
A comparative study was conducted to assess the difference
in protein aggregation between the SO and the SOF system by
means of a MFI technique, according to previous studies.20,21 In
this study, Asp aqueous solution (Asp sol.), IgG aqueous solu-
tion (IgG sol.), BSA aqueous solution (BSA sol.), and Lyso aque-
ous solution (Lyso sol.) were used as silicone-sensitive model
protein solutions, and the sample syringes were placed under
shaking condition. Another set of syringes was filled with wa-
ter for injection (JP) as reference. The number of particles with
different shape (AR ≥ 0.85) and (AR < 0.85) are compared in
Figures 3a and 3b, respectively.
As seen in Figure 3a, in case of water-filled syringes, a re-
markable number of circularly shaped subvisible particles (AR
≥ 0.85, regarded as oil droplets) was detected in the SO sys-
tem (average 963/mL), whereas much less or even a negligible
amount was found in the SOF system (2/mL), suggesting that
the proposed SOF system contributes a significantly smaller
number (p < 0.001, n = 10) of subvisible particles than the SO
system. It is known that subvisible particles could be formed by
the ingress of SO to the medium from the siliconized plunger
stopper or barrel.6,11,12 The observed phenomenon, therefore,
may be caused by the same reason. When protein formulation
was filled in syringes (Asp sol.), the number of subvisible parti-
cles (AR ≥ 0.85) drastically increased in the SO system (average
12,099/mL), whereas almost no change was observed in the SOF
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Figure 3. Comparison of the numbers of subvisible particles generated after filling water for injection (water), model protein solutions such as
asparaginase (Asp sol.), human IgG sol., bovine serum albumin (BSA sol.), and lysozyme (Lyso sol.) into the SO and the SOF system, determined
by MFI analysis. (a) AR < 0.85, (b) AR < 0.85. Data represent the mean values and corresponding standard deviations (n = 10 for water, n = 5
for model proteins).
system (average 73/mL), suggesting that the protein solution
may accelerate the ingress of SO by some interfacial interaction
or, that the ingressed oil subsequently forms protein–silicone-
oil aggregates (p < 0.05, n = 5). The same tendencies were also
observed in other model proteins (IgG sol., BSA sol., and Lyso
sol.).
Figure 3b presents a comparison of the measurement re-
sult for noncircular-shaped particles (AR < 0.85, regarded as
protein aggregates) between the SO and the SOF system. Anal-
ogous results were obtained in the two cases of water-filled and
protein-solution-filled syringes (Asp sol.). Namely, when the SO
system was used for protein formulation, an extremely large
number of particles was formed (average 46,659/mL), whereas
significantly fewer were generated in the SOF system (aver-
age 897/mL) (p < 0.05, n = 5). From the results of a previous
study, BSA was believed to be a positive control as it showed the
most dramatic SO-induced aggregation at pH 7.2.6 On the other
hand, Lyso was expected to be a negative control as no partic-
ular change was observed at pH 7.2. Because of the large error
bar, we cannot discuss all of the details of this result. However,
BSA showed a SO-induced aggregation even though the t value
was >0.05 (p value was 0.051 in case of AR < 0.85) and Lyso
showed a lesser impact of SO (p value was 0.40 in case of AR <
0.85). In the Lyso sample, relatively higher particle counts were
observed even in the SOF system. To obtain further informa-
tion, an additional study was conducted with noncoated plunger
stopper and syringe. As a result, after shaking samples, the par-
ticle counts increased even in the non-SO condition (data not
shown). This result suggests that the high particle counts were
not caused by SO but rather physical stress itself. Overall, the
same tendencies were observed in all model proteins. There-
fore, we assume that it can be minimized through a reduction
in the content of SO in protein pharmaceutical formulations.
It is interesting that a large number of circular particles (AR
≥ 0.85) was observed in the water filled SO system (average
963/mL), whereas the number of noncircular particles (AR <
0.85) was quite small (average 2/mL).
The observed decrease also suggests that SO droplets could
have the potential to induce protein aggregation in the various
protein solutions.
Although the detailed mechanism of the formation of pro-
tein aggregations is still obscure, all the results clearly prove
that SO causes the formation of subvisible particles and, hence,
that the SOF system based on the i-coatingTM technology is su-
perior to the SO system in terms of avoiding the formation of
subvisible particles in the syringe.
Container Closure Integrity
The CCI of the SOF system was tested by dye and microbial
penetration studies. Figure 4 schematically shows the configu-
ration of the sample syringe used for this study, and the results
of the dye penetration test using 1% crystal violet as marker.
The syringes with various headspaces were tested to examine
the influence of internal pressure. As listed in the table, all
samples showed very low absorbance (lower than the detection
limit), irrespective of the volume of the headspace, meaning
that the penetrated dye amount was almost negligible. Actu-
ally, the calculated concentration of crystal violet in the inner,
water-filled volume was less than 10−5 times that of the outer
solution. This result assures a sufficient CCI of the SOF system.
The results of a microorganism penetration study are shown
in Figure 5. After 14 days of incubation, the TSB culture
medium, filled in the SOF syringes and immersed in a bacterial
Yoshino et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:1520–1528, 2014 DOI 10.1002/jps.23945
RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology 1525
Figure 4. Experimental set up and results of the dye penetration study. (a) Schematic drawing of the configuration of sample syringe, (b) dye
concentration (absorbance at 590 nm) penetrated into inner volume across various headspaces. Data represent mean values and corresponding
standard deviations (n = 10).
Figure 5. Microorganism penetration study: the syringes filled with TSB culture medium were cultured for 14 days after the immersing
treatment into a bacterial broth (106 cfu/mL). (a) The SOF system showing all four investigated syringes. The inner solution remained clear
without any visual change. (b) Positive control (the SOF syringes with a pinhole on the barrel) of all five investigated syringes. The inner solution
became considerably turbid by the invasion and growth of microorganisms.
broth (106 cfu/mL), did not show any particular changes in its
appearance and the solution inside of the syringes remained
clear (Fig. 5a). By contrast, pin-holed SOF syringes (positive
control) showed a considerable change in that the medium be-
came turbid (Fig. 5b).
The judgments for the occurrence of microbial growth were
0/4 for the SOF syringe and 5/5 for its positive control. This
result indicates that the SOF system did not allow the penetra-
tion of microorganisms.
Dynamic Friction-Coefficient Analysis
In order to assess quantitatively the lubricious properties
of coated plunger stoppers, the dynamic friction coefficient
was determined using a continuous-loading surface prop-
erty tester. Butyl rubber sheets, pristine, coated by SO and
coated by the i-coatingTM technology, were used as model sam-
ples replacing the plunger stoppers used in the SO and the
SOF system, respectively, because of their identical surface
composition.
Figure 6 presents the comparison of the dynamic friction
coefficients determined for the three materials investigated:
uncoated butyl rubber sheet, SO-coated butyl rubber sheet,
and coated butyl rubber sheet. The purpose of this study was
to measure the smoothness of the solid surface property. As
evident from Figure 6, the dynamic friction coefficient of the
coated butyl rubber sheet was 10 times lower than that of
the uncoated butyl rubber sheet (p < 0.001, n = 9). Obser-
vation using SEM (Fig. 1) revealed that the surface of the
coated plunger stopper was much smoother than that of the
uncoated one. Therefore, it is assumed that the obtained result
clearly showed the degree of surface smoothness between un-
coated butyl rubber and the sheet coated using the i-coatingTM
technology.
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Figure 6. Comparison of the dynamic friction coefficient of (a) a pris-
tine butyl rubber surface, (b) a butyl rubber surface coated by SO, and
(c) a butyl rubber surface coated by i-coatingTM. Each sample sheet
(40 × 40 mm2, 1 mm in thickness) was analyzed for the dynamic fric-
tion coefficient using a continuous loading surface property tester. Data
represent mean values and corresponding standard deviations (n = 9).
Surprisingly, it is notable that the dynamic friction coeffi-
cient of the sheet coated using the i-coatingTM technology was
lower than that of the SO-coated butyl rubber sheet (p < 0.001,
n = 9). As mentioned above, this study measured the smooth-
ness of the solid surface property. However, according to a fluid
lubricant coating such as SO, it would be difficult to predict
the difference between coated butyl rubber sheets with solid
lubrication and that of the SO-coated butyl rubber sheet with
fluid lubrication as the SO on the surface is easily moved when
force is applied. In this measurement, a steel ball was placed
vertically on the sheet surface and pulled back horizontally
to measure the surface friction. However, in cases of plunger
stopper movement within the syringe, a concentric force was
generated by the plunger stopper expansion.
Among those differences, it is thought these conclusions have
been obtained only by comparing the material physical prop-
erties, that is, the apparent dynamic friction coefficients, of
the samples. They may not be completely representative of the
findings obtained using actual plunger stoppers. Although the
value of this study is the ability to simply obtain differences
as quantitative values, these results strongly indicate that the
application of i-coatingTM to a butyl rubber surface drastically
decreases the friction resistance of the surface without using
SO.
Gliding Force Measurement
A comparative study was conducted to reveal the difference
in the gliding force between the SO and the SOF system. To
simulate the condition under which syringes are actually used,
the specimens were stored at 40◦C for 12 weeks in advance.
The profiles of the gliding force of the SO and the SOF system
are shown in Figure 7.
As seen in Figure 7, both syringe systems provided differ-
ent gliding force profiles. The SO system showed a maximum
Figure 7. Comparison of the gliding force profiles between the SO
system (dotted line) and the SOF system (solid line). The sample sy-
ringes were measured after storage for 12 weeks at 40◦C, and the data
were corrected at a stroke of 200 mm/min.
gliding force of 9 N in the form of a sharp peak at a stroke
distance of 3 mm (break loose). The gliding force subsequently
reduced to a lower level of about 2 N. On the contrary, no signif-
icant difference between the break loose and gliding force was
observed in the SOF system. After the initial rise to about 3 N,
the gliding force gradually increased to the maximum value of
6 N at a stroke distance of 30 mm.
The observed difference in the gliding force profile is thought
to originate from the difference in the lubrication mechanism
of both syringe systems. Namely, in the SO system, as SO is
coated onto the surfaces of the barrel and the plunger stopper,
the SO on the barrel always provides additional lubricity while
the plunger stopper moves down in the barrel. Therefore, the
gliding force under steady-state conditions is lower compared
with the SOF system. In this case, however, because sufficient
SO cannot be supplied at the initial stage, a large gliding force is
required as a break loose force until the plunger stopper starts
to move. This type of profile is commonly observed in currently
available SO system including disposable types of syringes.
On the other hand, the SOF system has a lubricious silicone-
based resin that is coated on the plunger stopper instead of SO.
Even though the gliding force of the SOF system was a little
higher than in the SO system, it is far below the maximum
permissible value for actual use. This could be caused by the
absence of additional lubricity in the SOF syringes, supplied
by SO in the SO system, to reduce the friction force generated
during the movement of the plunger stopper. To confirm this,
the actual moving plunger stopper shape was observed using
a CCD camera. As a result, it was observed that the distance
of the two ribs decreased and the width of plunger stopper (be-
tween two ribs) increased (data not shown). This indicates that
the plunger stopper was compressed and the expansion force
increased before the plunger stopper moved. This conclusion is
also supported by the observed gradual increase in the gliding
force.
In order to examine further differences in the break loose
force between the SO and the SOF system, stability stud-
ies were performed at 4◦C, 25◦C, and 40◦C for 24 weeks. In
this study, the maximum force between 0 and 5 mm of stroke
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Figure 8. Break loose force changes of (a) the SO system and (b) the SOF system versus aging time at various temperature; 5◦C (•), 25◦C (),
and 40◦C (). Data represent mean values and corresponding standard deviations (n = 5).
distance was defined as “break loose force.” The results are
shown in Figures 8a and 8b.
As seen in Figure 8a, the break loose forces in the SO system
gradually increased with the lapse of time and finally reached
constant equilibrium values after 8 weeks. These constant val-
ues increased on increasing temperature (about 6 N at 5◦C,
8 N at 25◦C, and 10 N at 40◦C). On the other hand, as seen in
Figure 8b, no changes were observed in the break loose force
of the SOF system, irrespective of storage period and tempera-
ture. The constant break loose force value was about 3 N in all
investigated cases.
The temperature dependence of the break loose force ob-
served in the SO system could be attributed to the thermal
expansion of the plunger stopper. For more details, it is con-
sidered that the SO layer located between plunger stopper and
barrel is gradually spread out in response to the plunger stop-
per expansion on aging time, resulting in a thinner SO layer
that increases the initial friction (break loose force). The vis-
cosity of the SO may contribute to the observed temperature
dependence in various ways. On the other hand, in case of the
SOF syringe, in which the plunger stopper is coated chemically
with a silicone-based resin, the lubricity of the plunger stopper
hardly changes by temperature or aging time, as evidenced by
Figure 8b.
CONCLUSIONS
Through a series of comparative studies, it was demonstrated
that a newly developed SOF system prevents effectively the
formation of subvisible particles including both, SO droplets
and oil-induced aggregations. Furthermore, it was confirmed
by dye and microorganism penetration studies that the SOF
system assures a sufficient CCI. In addition, the SOF system
showed no significant difference between the break loose and
gliding force and did not change with aging time and tempera-
ture. Therefore, the SOF syringes enable to minimize the risk
of unexpected rapid release during aspiration and unexpected
gliding force change during storage. All these results prove
that the newly developed SOF system using the i-coatingTM
technology has great advantages compared with the current
SO system.
In conclusion, the proposed novel SOF system has a great
potential and represents a novel alternative that can achieve
a very low level of subvisible particles, secure CCI, and the
absence of a break loose force. In particular, no risk of SO-
induced aggregation and very low level of subvisible particles
can bring additional value to the highly sensitive biotech drug
market.
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